Sign into an existing account

Here is the document

CBER Plans for Monitoring COVID-19
Vaccine Safety and Effectiveness
https://www.fda.gov/media/143557/download

first Jab Dec 14th 2020
https://www.smithsonianmag.com/smithsonian-institution/first-vial-used-us-covid-19-vaccinations-joins-smithsonian-collections-180977194/

FDA&CDC Knew
https://www.bitchute.com/video/0n0hl9lLQabE/

Active Surveillance
Passive Surveillance
Using BEST, CBER plans to monitor about 15 adverse events External Link Disclaimerthat have been seen with the deployment of previous vaccines but have yet to be associated with a safety concern for an authorized COVID-19 vaccine at this time. CBER further plans to use the BEST system to conduct more in-depth analyses should a safety concern be identified from sources such as VAERS.


https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-vaccine-safety-surveillance
The Center for Biologics Evaluation and Research (CBER) at the FDA is monitoring the safety of authorized COVID-19 vaccines through both passive and active safety surveillance systems. CBER is doing so in collaboration with the Centers for Disease Control and Prevention (CDC), the Center for Medicare and Medicaid Services (CMS), the Department of Veterans Affairs (VA), and other academic and large non-government healthcare data systems. In addition, CBER participates actively in ongoing international pharmacovigilance efforts, including those organized by the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO). These efforts are in addition to the pharmacovigilance efforts being undertaken by the individual manufacturers for authorized vaccines. A coordinated and overlapping approach using state-of the art technologies has been implemented.